A Phase 2 Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) With Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients With Primary Operable HER2-Positive Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 05 Jun 2018
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab (Primary)
- Indications Breast cancer; Male breast cancer
- Focus Therapeutic Use
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 22 Apr 2018 Status changed from active, no longer recruiting to completed.
- 27 Sep 2017 Status changed from recruiting to active, no longer recruiting.